PRNewsWire
19 Sept 2025, 18:35 UTC · 51w ago
Verdict
Headline takes no side. We score PEPG −1.00 across three claims — strongly bearish.
−1.00strongly bearish
More negative than 96% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
A federal securities lawsuit alleges that PepGen Inc. misrepresented the effectiveness and safety of its PGN-EDO51 drug candidate.
More negative than 98% of claims this week
The CONNECT2 study is alleged to be dangerous or deficient for the purposes of U.S. FDA approval.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More negative than 96% of claims this week
Kuehn Law is investigating whether PepGen officers and directors breached their fiduciary duties to shareholders.
More negative than 80% of claims this week
Which stocks this story touches
More negative than 96% of ticker scores this week
The company is facing a shareholder litigation investigation regarding alleged misrepresentations of drug safety and efficacy.
More negative than 96% of ticker scores this week
The company is mentioned as being under investigation by a shareholder litigation law firm.
More negative than 96% of ticker scores this week
The company is mentioned as being under investigation by a shareholder litigation law firm.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
45m ago
+40.7%
Price is moving against the score
$2.88 vs $2.05 close before publication (Sep 18) · not market-adjusted
PEPG chart →
